

Please cancel claims 88 and 90 without prejudice.

91. (Twice Amended) A method for stimulating the production of an N-CAM or L1 isoform in a neuronal cell, comprising contacting the neuronal cell with a morphogen comprising a dimeric protein having an amino acid sequence selected from the group consisting of a sequence:

- (a) having the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO:5;
- (b) having the amino acid sequence of the C-terminal seven-cysteine skeleton on human OP-1;
- (c) defined by Generic Sequence 6, SEQ ID NO:31; and
- (d) defined by OPX, SEQ ID NO: 29.

97. (Twice Amended) A method for decreasing neuronal cell death associated with a neuropathy, comprising contacting said neuronal cell with a morphogen selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.

99. (Twice Amended) A method for decreasing neuronal cell death associated with a chemical or physical injury, comprising contacting said neuronal cell with a morphogen selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.

105. (Amended) The method of claim 97 or 99, wherein the morphogen is human OP-1.

106. (Amended) The method of claim 97 or 99, wherein the morphogen is mouse OP-1.

**RECEIVED**  
JAN 14 2002  
OFFICE OF PETITIONS